التفاصيل البيبلوغرافية
| العنوان: |
Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. |
| المؤلفون: |
Brown, Victoria T., Antol, Dana Drzayich, Racsa, Patrick N., Ward, Melea A., Naidoo, Jarushka |
| المصدر: |
Cancer Investigation; Nov 2021, Vol. 39 Issue 10, p789-796, 8p |
| مصطلحات موضوعية: |
IMMUNE checkpoint inhibitors, RETROSPECTIVE studies, DISEASE incidence, CANCER patients, HEALTH insurance reimbursement, TUMORS, ADVERSE health care events, MEMBRANE proteins, TERMINATION of treatment, MEDICAL prescriptions, IMMUNOTHERAPY, MEDICARE, DRUG administration, DRUG dosage |
| مستخلص: |
We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. These data underscore the needs for tailored irAE diagnostic and management pathways. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Investigation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
